Bicocca Open Archive

Logo unimib boa
ZAMBELLI, ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 14.747
NA - Nord America 6.599
EU - Europa 3.537
SA - Sud America 2.216
Continente sconosciuto - Info sul continente non disponibili 672
AF - Africa 245
OC - Oceania 7
Totale 28.023
Salva come PNG Salva come JPEG
Nazione #
VN - Vietnam 6.426
US - Stati Uniti d'America 6.176
SG - Singapore 3.140
CN - Cina 2.069
BR - Brasile 1.674
IT - Italia 1.637
HK - Hong Kong 1.183
BD - Bangladesh 650
RU - Federazione Russa 477
KR - Corea 303
DE - Germania 300
FR - Francia 292
CA - Canada 222
IN - India 201
AR - Argentina 178
ID - Indonesia 138
FI - Finlandia 129
IQ - Iraq 121
SE - Svezia 121
GB - Regno Unito 114
EC - Ecuador 107
MX - Messico 105
IE - Irlanda 84
UA - Ucraina 78
ZA - Sudafrica 78
PK - Pakistan 77
CO - Colombia 75
TR - Turchia 73
AT - Austria 64
NL - Olanda 64
PY - Paraguay 60
PH - Filippine 48
SA - Arabia Saudita 48
UZ - Uzbekistan 44
JP - Giappone 43
VE - Venezuela 41
CL - Cile 40
ES - Italia 39
MA - Marocco 37
TN - Tunisia 30
MY - Malesia 25
JO - Giordania 23
PL - Polonia 23
RO - Romania 23
PE - Perù 22
CR - Costa Rica 21
KE - Kenya 21
CH - Svizzera 18
EG - Egitto 18
DZ - Algeria 16
JM - Giamaica 16
AE - Emirati Arabi Uniti 14
UY - Uruguay 14
DK - Danimarca 13
NP - Nepal 13
ET - Etiopia 12
AZ - Azerbaigian 11
OM - Oman 11
GT - Guatemala 10
PS - Palestinian Territory 10
TH - Thailandia 9
TT - Trinidad e Tobago 9
HN - Honduras 8
NI - Nicaragua 8
AL - Albania 7
IL - Israele 7
LB - Libano 7
AU - Australia 6
CZ - Repubblica Ceca 6
KZ - Kazakistan 6
LT - Lituania 6
PT - Portogallo 6
BG - Bulgaria 5
DO - Repubblica Dominicana 5
GE - Georgia 5
KW - Kuwait 5
BB - Barbados 4
BE - Belgio 4
HU - Ungheria 4
IR - Iran 4
LK - Sri Lanka 4
NG - Nigeria 4
PA - Panama 4
SN - Senegal 4
SY - Repubblica araba siriana 4
TG - Togo 4
TW - Taiwan 4
AM - Armenia 3
AO - Angola 3
BH - Bahrain 3
BO - Bolivia 3
BY - Bielorussia 3
EU - Europa 3
GA - Gabon 3
HR - Croazia 3
KG - Kirghizistan 3
LV - Lettonia 3
PR - Porto Rico 3
SV - El Salvador 3
BA - Bosnia-Erzegovina 2
Totale 27.307
Salva come PNG Salva come JPEG
Città #
Ho Chi Minh City 2.029
Hanoi 1.665
Singapore 1.343
Hong Kong 1.168
Ashburn 780
San Jose 753
Hefei 700
Milan 491
Seoul 298
Council Bluffs 274
Ann Arbor 259
Los Angeles 251
Chicago 246
Rome 198
Da Nang 197
Lauterbourg 188
Beijing 176
Haiphong 175
New York 161
The Dalles 158
Dallas 153
Quận Bình Thạnh 140
Buffalo 135
Ha Long 128
Fairfield 126
Frankfurt am Main 126
São Paulo 124
Biên Hòa 121
Santa Clara 118
Toronto 110
Vũng Tàu 108
Woodbridge 108
Ninh Bình 104
Quận Một 95
Chandler 94
Thái Nguyên 91
Hải Dương 89
Seattle 83
Bắc Ninh 82
Dublin 82
Houston 82
Jakarta 79
Helsinki 75
Can Tho 72
Nuremberg 68
Moscow 67
Boardman 63
Wilmington 63
Rio de Janeiro 61
Phủ Lý 57
Quận Phú Nhuận 53
Baghdad 52
Turin 52
Figino 49
Vinh 49
Bắc Giang 45
Jacksonville 45
Lappeenranta 45
Shanghai 45
Mexico City 43
Quito 41
Dearborn 39
Tashkent 38
Thái Bình 38
Cambridge 37
Quận Tân Phú 37
Guangzhou 36
Atlanta 35
Quận Sáu 35
Paris 34
Lang Son 32
Naples 32
Curitiba 31
Lấp Vò 31
Princeton 31
Vienna 31
Vĩnh Tường 31
Dhaka 30
Brasília 29
Asunción 28
Thu Dau Mot 28
Tokyo 28
Guayaquil 27
Hòa Bình 27
Kent 27
Munich 27
Phoenix 27
Nam Định 26
Điện Bàn 26
Brooklyn 25
Quảng Ninh 24
Quận Năm 24
San Francisco 24
Belo Horizonte 23
Cà Mau 23
Johannesburg 23
Porto Alegre 23
Nanjing 22
Quận Bốn 22
Quận Hai 22
Totale 16.066
Salva come PNG Salva come JPEG
Nome #
Long-term survival in a fraction of patients with metastatic breast cancer who received consolidation therapy with high-dose chemotherapy and autologous stem cell transplant between 2000 and 2015: an EBMT registry-based study 793
Breast and renal cancer-Derived endothelial colony forming cells share a common gene signature 623
Short commentaries on data published by Petit et al. on locoregional risk after lipofilling in breast cancer patients 552
Analysis of SEMA6B gene expression in breast cancer: Identification of a new isoform 516
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study 466
Efficacy and safety of T-DM1 in the ‘common-practice’ of HER2+ advanced breast cancer setting: a multicenter study 383
No correlation between plasma D-dimer levels and lymph node involvement in operable breast cancer 375
Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms 353
A male patient with acromegaly and breast cancer: treating acromegaly to control tumor progression 348
Targeting triple negative breast cancer: Is p53 the answer? 345
Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy 329
Management and Survival of Pleural Mesothelioma: A Record Linkage Study 307
Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival 297
Retinoids and breast cancer: from basic studies to the clinic and back again 290
Remodelling of the Ca2+ signalling machinery in endothelial progenitor cells isolated from breast cancer patients 288
Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study 264
Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer 258
Effectiveness of trastuzumab in first-line her2+ metastatic breast cancer after failure in adjuvant setting: A controlled cohort study 248
Pulmonary function and complications following chemotherapy and stem cell support in breast cancer 247
Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: a large cohort study from clinical practice. 242
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer 238
Bone Metastases and Skeletal Complications: Information and Involvement of Patients with Cancer in the Treatment Pathway 233
Trastuzumab-related cardiotoxicity in early breast cancer: A cohort study 232
Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions 228
Erratum: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9 (31877-31887) DOI: 10.18632/oncotarget.25874) 221
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study 207
Incorporating radiomic MRI models for presurgical response assessment in patients with early breast cancer undergoing neoadjuvant systemic therapy: Collaborative insights from breast oncologists and radiologists 205
Surrogate endpoints for overall survival in randomized clinical trials testing antibody-drug conjugates 200
Correction: Everolimus (Eve) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9:77 (34639-34640) DOI: 10.18632/oncotarget.25874) 199
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial 194
Digital innovations in breast cancer care: exploring the potential and challenges of digital therapeutics and clinical decision support systems 192
A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy 192
Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study 192
Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors 190
Charting the Course in Sequencing Antibody-Drug Conjugates in Breast Cancer 190
Sex-Related Differences in Immunotherapy Toxicities: Insights into Dimorphic Responses 189
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies 187
A network-based data integration approach to support drug repurposing and multi-Target therapies in triple negative breast cancer 182
ACUTE UPPER GASTROINTESTINAL BLEEDING (AUGB) IN ITALY: AN INTERIM ANALYSIS OF THE ORGANIZATIONAL ASPECTS CARING AN EVOLVING DISEASE 181
Empowerment, Pain Control, and Quality of Life Improvement in Early Triple-Negative Breast Cancer Patients through Pain Neuroscience Education: A Prospective Cohort Pilot Study Protocol (EMPOWER Trial) 176
Optimizing abemaciclib-induced diarrhea management in patients with breast cancer: a pragmatic 2-group study using a postbiotic microbiota stabilizer 173
Transfusion Strategy and Death Risk in Patients with Acute Non-Variceal Upper Gastro Intestinal Bleeding (NV-UGIB) in Italy: A Prospective Multicenter Observational Study 171
BRCA Testing for Patients Treated in Italy: A National Survey of Breast Centers Associated with Senonetwork 171
Deep Neural Network Integrated into Network-Based Stratification (D3NS): A Method to Uncover Cancer Subtypes from Somatic Mutations 169
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study 167
Common Misconceptions about Diet and Breast Cancer: An Unclear Issue to Dispel 164
Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry 162
Alternative Splicing in Adhesion- and Motility-Related Genes in Breast Cancer 161
Loco-Regional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancer Patients Undergoing Front-Line Chemotherapy 160
Multinational characterization of neurological phenotypes in patients hospitalized with COVID-19 157
Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patients 157
Decoding NATALEE and MonarchE eligibility criteria in a real-world cohort of early breast cancer patients 157
Tyrosine kinase inhibitors and QTc intervals: A class effect 153
ONCO-i2b2: improve patients selection through CBR techniques with heterogeneous distance functions 151
Empowering beyond Pain: Pain Neuroscience Education Interventions in Breast Cancer Survivorship Care 151
Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors 151
Hereditary Cancer Syndromes: A Comprehensive Review with a Visual Tool 150
Bone-Active Drugs in Pre-Menopausal Women with Breast Cancer Under Hormone Deprivation Therapies 148
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial 146
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study 145
Unlocking methodological insights on oncology efficacy endpoints: from statistical to clinical and vice versa. Letter to the editor regarding ‘Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3’ by M. P. Goetz et al 143
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer - Immun-HER trial (GOIRC-01-2016) 142
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project 142
The central role of pathology labs in breast cancer precision oncology: a call for action 140
i2b2 to optimize patients enrollment 139
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review 139
Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research 138
Real-world use of multigene signatures in early breast cancer: differences to clinical trials 138
Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study 137
Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein Interaction 136
Long-term kidney function recovery and mortality after COVID-19-associated acute kidney injury: An international multi-centre observational cohort study 135
The Predictive Role of Radiomics in Breast Cancer Patients Imaged by [18F]FDG PET: Preliminary Results from a Prospective Cohort 134
Correction to: Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors (Journal of Endocrinological Investigation, (2023), 47, 2, (433-442), 10.1007/s40618-023-02174-5) 133
Prevalence of treatment-related adverse events (TRAEs) with antibody-drug conjugates in metastatic breast cancer patients: A systematic review and meta-analysis 132
The Role of Female Reproductive Hormones in the Association between Migraine and Breast Cancer: An Unanswered Question 131
Analysis of Italian BRCA1/2 Pathogenic Variants Identifies a Private Spectrum in the Population from the Bergamo Province in Northern Italy 131
Characterization of long COVID temporal sub-phenotypes by distributed representation learning from electronic health record data: a cohort study 130
Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review 128
COVID-19 Sequelae and the Host Pro-Inflammatory Response: An Analysis From the OnCovid Registry 128
Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective 126
Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments 125
Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies 125
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry 124
Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants 121
Clinical Review on the Management of Breast Cancer Visceral Crisis 121
Evolving phenotypes of non-hospitalized patients that indicate long COVID 120
Corrigendum to “Prevalence of treatment-related adverse events (TRAEs) with antibody-drug conjugates in metastatic breast cancer patients: A systematic review and meta-analysis” [Crit. Rev. Oncol./Hematol. 204 (2024) 104527](S1040842824002701)(10.1016/j.critrevonc.2024.104527) 120
Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives 118
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer 117
Unlocking the Potential of Circulating miRNAs in the Breast Cancer Neoadjuvant Setting: A Systematic Review and Meta-Analysis 117
Unveiling the Potential of Cyclin-Dependent Kinases 4 and 6 Inhibitors Beyond Progression in Hormone Receptor Positive/Human Epidermal Growth Factor Negative Advanced Breast Cancer – A Clinical Review 116
International comparisons of laboratory values from the 4CE collaborative to predict COVID-19 mortality 115
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors 114
The Impact of Different Patterns of Residual Disease on Long-Term Oncological Outcomes in Breast Cancer Patients Treated with Neo-Adjuvant Chemotherapy 112
Real-World Effectiveness of Denosumab and Bisphosphonates on Risk of Vertebral Fractures in Women with Breast Cancer Undergoing Treatment with Aromatase Inhibitors 111
Acute respiratory distress syndrome after SARS-CoV-2 infection on young adult population: International observational federated study based on electronic health records through the 4CE consortium 111
PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy 111
Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach 111
Multigene signatures for early breast cancer in clinical practice: A report of the Lombardy genomic assays for breast cancer working group 108
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev. 114 (2023) 102511] (Cancer Treatment Reviews (2023) 114, (S0305737223000026), (10.1016/j.ctrv.2023.102511)) 108
Totale 19.743
Salva come PNG Salva come JPEG
Categoria #
all - tutte 71.088
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 71.088
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022184 0 23 36 12 4 13 5 8 8 21 25 29
2022/2023357 35 123 36 22 22 49 0 22 22 1 15 10
2023/2024213 5 6 11 8 32 50 42 8 19 0 7 25
2024/20254.752 31 74 15 28 60 646 313 116 318 644 455 2.052
2025/202620.025 4.958 3.266 1.345 2.022 831 530 1.557 763 1.050 1.195 828 1.680
2026/20271.428 845 583 0 0 0 0 0 0 0 0 0 0
Totale 28.023